What is Celcuity?
Celcuity operates at the intersection of diagnostics and therapeutics within the biotechnology sector. The company's core innovation, the CELsignia companion diagnostic platform, is designed to identify specific patient subgroups who are most likely to respond to particular targeted therapies. This approach allows Celcuity to pursue in-licensing and development of molecularly targeted therapies that align with the diagnostic markers identified by CELsignia. By focusing on precision medicine, Celcuity seeks to optimize treatment efficacy and improve outcomes for cancer patients, marking a significant development in the pursuit of personalized cancer care.
How much funding has Celcuity raised?
Celcuity has raised a total of $117.5M across 6 funding rounds:
Multiple Rounds
$31.1M
Debt
$350K
Stock Offering
$24M
Debt
$62M
Debt (2017): $5.8M, investors not publicly disclosed
Debt (2017): $2.6M, investors not publicly disclosed
Stock Issuance/Offering (2017): $22.8M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Stock Issuance/Offering (2021): $24M backed by Craig-Hallum Capital Group
Debt (2024): $62M with participation from Oxford Finance
Key Investors in Celcuity
Oxford Finance
Oxford Finance is a specialty finance firm that offers flexible financial solutions to healthcare and life sciences companies worldwide, indicating a focus on supporting companies like Celcuity through debt financing.
Craig-Hallum Capital Group
Craig-Hallum Capital Group is an investment bank that provides financial advisory and capital raising services, suggesting their involvement in Celcuity's equity financing rounds.
What's next for Celcuity?
With the recent major strategic investment and a robust history of capital raising totaling $117.5M, Celcuity is poised for accelerated development and potential commercialization of its integrated therapeutic and diagnostic solutions. The company's focus on identifying patient populations for approved targeted therapies suggests a strategy aimed at leveraging existing drug approvals, potentially streamlining the path to market. Future endeavors will likely involve further clinical validation of the CELsignia platform and the advancement of its in-licensed therapeutic candidates, aiming to solidify its position in the competitive landscape of precision oncology.
See full Celcuity company page
